Bayer: Wired Health 2025 - IA e Nuove Frontiere delle Terapie Geniche

Bayer: Wired Health 2025 – IA e Nuove Frontiere delle Terapie Geniche

177 0

Among the panels featuring researchers and stakeholders, one area of particular interest is gene and cell therapies.

“This represents a true innovation in medicine, enabling us to tackle diseases that were previously incurable by allowing us to intervene on genes or modify a patient’s cells, for instance, by correcting a genetic mutation or training immune cells to better attack tumors,” stated Luigi Naldini, Director of the San Raffaele Telethon Institute for Gene Therapy, describing this field of medical research as “a clinical reality; thousands of patients have already been treated for both genetic disorders and cancer with these therapeutic innovations.”

Among the key players active in this sector is Bayer. “We have focused on gene and cell therapies as a new frontier for innovation and the treatment of important diseases,” emphasized Arianna Gregis, Country Head Pharmaceuticals Bayer Italia. “In recent years, we have invested over 3.5 billion euros to acquire two gene and cell therapy platforms called Blue Rock and ASKBio, which aim to bring excellence in this field.”

“A concrete outcome is our commitment concerning Parkinson’s disease. We know that many patients are still waiting for a cure, and both BlueRock and ASKBio are harnessing cellular and genetic potential to find a tangible solution,” she continued.

The results from this partnership have been swift: the most significant being the RMAT (Regenerative Medicine Advanced Therapy) designation for the experimental gene therapy for Parkinson’s developed by AskBio, granted by the FDA (Food and Drug Administration). This designation has allowed research to advance with both BlueRock’s cellular therapy and AskBio’s gene therapy.

Bayer’s focus on research in this field also includes exploring potential applications of Artificial Intelligence, particularly to expedite processes.

“For Bayer, artificial intelligence serves as an accelerator in the entire research and development process. We have set an ambitious goal to accelerate and reduce our research and development timelines by 40% by 2030,” explained Gregis. “In this context, we can highlight two significant collaborations, one with a tech giant like Google and another with an American company called Recursion, which aims to leverage predictive machine learning mechanisms to discover new therapeutic targets and therapies.”

Specifically, through the collaboration with Recursion, it was possible to “identify a new therapeutic target in just 18 months instead of the usual standard of 42.”
Naturally, the field of gene and cell therapies also faces challenges and demands.

According to Naldini, “having proven the principle of these therapies, we need to keep them available on the market sustainably. They are not only transformative but also complex to produce and, obviously, very costly. If there are only a few patients, as in rare diseases, these therapies become financially challenging to sustain. It’s a challenge for everyone because research has produced innovation, and we must keep it available and accessible to patients.”

“Driving innovation means starting from listening to patient needs, and to do this, we need to forge valuable alliances with all stakeholders in the healthcare system in Italy and globally. Thus, we collaborate with clinicians, universities, startups, political and institutional stakeholders to envision diagnosis and treatment pathways that center around people,” Gregis emphasized.

Would you like to publish contents from Italpress.com on your website or promote your activities on ours and our partner publications? Contact us at [email protected]



Fonte notizia

Related Post